Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active …

C Loo, N Glozier, D Barton, BT Baune… - The British Journal of …, 2023 - cambridge.org
BackgroundPrior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

The molecular pathophysiology of depression and the new therapeutics

H Tian, Z Hu, J Xu, C Wang - MedComm, 2022 - Wiley Online Library
Major depressive disorder (MDD) is a highly prevalent and disabling disorder. Despite the
many hypotheses proposed to understand the molecular pathophysiology of depression, it is …

Effects of different doses of esketamine intervention on postpartum depressive symptoms in cesarean section women: a randomized, double-blind, controlled clinical …

SQ Yang, YY Zhou, ST Yang, XY Mao, L Chen… - Journal of Affective …, 2023 - Elsevier
Background The optimal dosage and method of esketamine for postpartum depressive
symptoms (PDS) are unclear. We conducted a randomized controlled trial (RCT) to …

[HTML][HTML] A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment …

PR Shiroma, P Thuras, J Wels, CS Albott… - Translational …, 2020 - nature.com
The strategy of repeated ketamine in open-label and saline-control studies of treatment-
resistant depression suggested greater antidepressant response beyond a single ketamine …

Psilocybin and MDMA for the treatment of trauma-related psychopathology

CIV Bird, NL Modlin, JJH Rucker - International Review of …, 2021 - Taylor & Francis
This review examines the role of trauma in psychiatric morbidity and analogous
psychoneurobiological changes. Trauma is a necessary criterion for Post-Traumatic Stress …

Ketamine for depression

LA Jelen, JM Stone - International review of psychiatry, 2021 - Taylor & Francis
Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-
Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for …

RETRACTED ARTICLE: Anatomy of a Woebot®(WB001): agent guided CBT for women with postpartum depression

A Darcy, A Beaudette, E Chiauzzi… - Expert Review of …, 2022 - Taylor & Francis
Statement of Retraction Retraction: Anatomy of a Woebot®(WB001): Agent Guided CBT for
women with postpartum depression We, the Editor and Publisher of Expert Review of …

Ketamine in neuropsychiatric disorders: an update

JN Johnston, B Kadriu, C Kraus, ID Henter… - …, 2024 - nature.com
The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …

The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research

H Gill, B Gill, NB Rodrigues, O Lipsitz… - Neuroscience & …, 2021 - Elsevier
Replicated evidence has documented cognitive deficits in populations with treatment-
resistant depression (TRD). Approximately 40% of patients with MDD present with …

Toll-like receptor signaling in depression

LK Figueroa-Hall, MP Paulus, J Savitz - Psychoneuroendocrinology, 2020 - Elsevier
Depression is one of the most prevalent, disabling, and costly mental illnesses currently
affecting over 300 million people worldwide. A subset of depressed patients display …